1. Henderson RLJr, Fleischer ABJr, Feldman SR: Allergists and dermatologists have far more expertise in caring for patients with urticaria than other specialists. J Am Acad Dermatol 43:1084, 2000
2. Gaig P et al: Epidemiology of urticaria in Spain. J Invest Allergol Clin Immunol 14:214, 2004
3. Weidner C et al: Acute effects of substance P and
calcitonin gene-related peptide in human skin–A microdialysis study.
J Invest Dermatol 115:1015, 2000
4. Petersen L, Church M, Skov PS: Histamine is released in the wheal but not the flare following challenge of human skin in vivo: A microdialysis study. Clin Exp Allergy 27:284, 1997
5. Sun Y et al: Cellular basis of itch sensation. Science 325:1531, 2009
6. Gorevic P, Kaplan A: The physical urticarias. Int J Dermatol 19:417, 1980
7. Soter N: Physical urticaria/angioedema. Semin Dermatol 6:302, 1987
8. Zweiman B et al: Sequential patterns of inflammatory events during developing and expressed skin late-phase reactions. J Allergy Clin Immunol 105:776, 2000
9. Leznoff A et al: Association of chronic urticaria and angioedema with thyroid autoim. Arch Dermatol 119:636, 1983
10. Leznoff A, Sussman G: Syndrome of idiopathic chronic urticaria and angioedema with thyroid autoimmunity: A study of 90 patients. J Allergy Clin Immunol 84:66, 1989
11. Kaplan A, Finn A: Autoimmunity and the etiology of chronic urticaria. Can J Allergy Clin Immunol 4:286, 1999
12. Kikuchi Y, Fann T, Kaplan A: Antithyroid antibodies in chronic urticaria and angioedema. J Allergy Clin Immunol 112:218, 2003
13. Gruber B et al: Prevalence and functional role of anti-IgE autoantibodies in urticarial syndromes. J Invest Dermatol 90:213, 1988
14. Grattan C et al: Preliminary identification of a low molecular weight serological mediator in chronic idiopathic urticaria. Br J Dermatol 119:179, 1998
15. Grattan C et al: A serological mediator in chronic idiopathic urticaria–A clinical, immunological and histological evaluation. Br J Dermatol 114:583, 1986
16. Hide M et al: Autoantibodies against the high-affinity IgE receptor as a cause of histamine release in chronic urticaria. N Engl J Med 328:1599, 1993
17. Grattan C et al: Detection of circulating histamine releasing autoantibodies with functional properties of anti-IgE in chronic urticaria. Clin Exp Allergy 21:695, 1992
18. Greaves M: Chronic urticaria. J Allergy Clin Immunol 105:664, 2000
19. Fiebiger E et al: Serum IgG autoantibodies directed against the alpha chain of Fc epsilon RI: a selective marker and pathogenetic factor for a distinct subset of chronic urticaria patients? J Clin Invest 96:2606, 1995
20. Tong L et al: Assessment of autoimmunity in patients with chronic urticaria. J Allergy Clin Immunol 99:461, 1997
21. Zweiman B et al: Characteristics of histamine-releasing activity in the sera of patients with chronic idiopathic urticaria. J Allergy Clin Immunol 98:89, 1996
22. Kikuchi Y, Kaplan A: Mechanisms of autoimmune activation of basophils in chronic urticaria. J Allergy Clin Immunol 107:1056, 2001
23. Ferrer M, Kinet J, Kaplan A: Comparative studies of functional and binding assays for IgG anti-Fc(epsilon)RIalpha (alpha-subunit) in chronic urticaria. J Allergy Clin Immunol 101:672, 1998
24. Ferrer M, Luquin E, Kaplan A: IL3 effect on basophils histamine release upon stimulation with chronic urticaria sera. Allergy 58:802, 2003
25. Ferrer M et al: Secretion of cytokines, histamine and leukotrienes in chronic urticaria. Int Arch Allergy Immunol 129:254, 2002
26. Wedi B et al: Chronic urticaria serum induces histamine release, leukotriene production, and basophil CD63 surface expression–inhibitory effects ofanti-inflammatory drugs. J Allergy Clin Immunol 105:552, 2000
27. Niimi N et al: Dermal mast cell activation by autoantibodies against the high affinity IgE receptor in chronic urticaria. J Invest Dermatol 106:1001, 1996
28. Ferrer M, Nakazawa K, Kaplan A: Complement dependence of histamine release in chronic urticaria. J Allergy Clin Immunol 104:169, 1999
29. Fiebiger E et al: Anti-FcepsilonRIalpha autoantibodies in autoimmune-mediated disorders. Identification of a structure-function relationship. J Clin Invest 101:243, 1998
30. Ling M et al: Importance of Antigen Selection in the Detection of Autoantibodies against FceRIa in Chronic Urticaria Patients, in. Lenexa, KS
31. Soundararajan S et al: Functional assessment of pathogenic IgG subclasses in chronic autoimmune urticaria. J Allergy Clin Immunol 115:815, 2005
32. Horn M et al: Human anti-FcepsilonRIalpha autoantibodies isolated from healthy donors cross-react with tetanus toxoid. Eur J Immunol 29:1139, 1999
33. Horn M et al: Conditional autoimmunity mediated by human natural anti-Fc(epsilon)RIalpha autoantibodies? FASEB J 15:2268, 2001
34. Pachlopnik J et al: Natural anti-FcepsilonRIalpha autoantibodies may interfere with diagnostic tests for autoimmune urticaria. J Autoimmun 22:43, 2004
35. Kikuchi Y, Kaplan A: A role for C5a in augmenting IgG-dependent histamine release from basophils in chronic urticaria. J Allergy Clin Immunol 109:114, 2002
36. Elias J, Boss E, Kaplan A: Studies of the cellular infiltrate of chronic idiopathic urticaria: Prominence of T-lymphocytes, monocytes, and mast cells. J Allergy Clin Immunol 78:914, 1986
37. Nettis E et al: Mast-cell phenotype in urticaria. Allergy 56:915, 2001
38. Smith C et al: Mast cell number and phenotype in chronic idiopathic urticaria. J Allergy Clin Immunol 96:360, 1995
39. Natbony S et al: Histologic studies of chronic idiopathic urticaria. J Allergy Clin Immunol 71:177, 1983
40. Haas N, Schadendorf D, Henz B: Differential endothelial adhesion molecule expression in early and late whealing reactions. Int Arch Allergy Immunol 115:210, 1998
41. Sabroe R et al: Cutaneous inflammatory cell infiltrate in chronic idiopathic urticaria: Comparison of patients with and without anti-FcepsilonRI or anti-IgE autoantibodies. J Allergy Clin Immunol 103:484, 1999
42. Peters M et al: Localization of eosinophil granule major basic protein in chronic urticaria. J Invest Dermatol 81:39, 1983
43. Grattan C et al: The pathology of the autologous serum skin test response in chronic urticaria resembles IgE-mediated late-phase reactions. Int Arch Allergy Immunol 93:198, 1990
44. Haas N, Toppe E, Henz B: Microscopic morphology of different types of urticaria. Arch Dermatol 134:41, 1998
45. Lee K et al: Increased expression of endothelial cell adhesion molecules due to mediator release from human foreskin mast cells stimulated by autoantibodies in chronic urticaria sera. J Invest Dermatol 118:658, 2002
46. Ying S et al: C-C chemokines in allergen-induced late-phase cutaneous responses in atopic subjects: Association of eotaxin with early 6-hour eosinophils, and of eotaxin-2 and monocyte chemoattractant protein-4 with the later 24-hour tissue eosinophilia, and relationship to basophils and other C-C chemokines (monocyte chemoattractant protein-3 and RANTES). J Immunol 163:3976, 1999
47. Sabroe R et al: Classification of anti-FcepsilonRI and anti-IgE autoantibodies in chronic idiopathic urticaria and correlation with disease severity. J Allergy Clin Immunol 40:492, 2002
48. Kern F, Lichtenstein L: Defective histamine release in chronic urticaria. J Clin Invest 57:1369, 1976
49. Sabroe R et al: Anti-Fc(episilon)RI auto antibodies and basophil histamine releasability in chronic idiopathic urticaria. J Allergy Clin Immunol 102:651, 1998
50. Grattan C et al: Flow cytometric analysis of basophil numbers in chronic urticaria: Basopenia is related to serum histamine releasing activity. Clin Exp Allergy 27:1417, 1997
51. Vonakis B et al: Basophil FcepsilonRI histamine release parallels expression of Src-homology 2-containing inositol phosphatases in chronic idiopathic urticaria. J Allergy Clin Immunol 119:441, 2007
52. Luquin E, Kaplan A, Ferrer M: Increased responsiveness of basophils of patients with chronic urticaria to sera but hypo-responsiveness to other stimuli. Clin Exp Allergy 35:456, 2005
53. Asero R et al: Activation of the tissue factor pathway of blood coagulation in patients with chronic urticaria. J Allergy Clin Immunol 119:705, 2007
54. Asero R: Predictive value of autologous plasma skin test for multiple nonsteroidal anti-inflammatory drug intolerance. Int Arch Allergy Immunol 144:226, 2007
55. Cugno M et al: Expression of tissue factor by eosinophils in patients with chronic urticaria. Int Arch Allergy Immunol 148:170, 2009
56. Puccetti A et al: In chronic idiopathic urticaria autoantibodies against Fc epsilonRII/CD23 induce histamine release via eosinophil activation. Clin Exp Allergy 35:1599, 2005
57. Margolius H: Tissue kallikreins structure, regulation, and participation in mammalian physiology and disease. Clin Rev Allergy Immunol 16:337, 1998
58. Jacobson S, Kritz M: Some data on two purified kininogens from human plasma. Br J Pharmacol 29:25, 1967
59. Muller-Esterl W et al: Limited proteolysis of human low-molecular-mass kininogen by tissue kallikrein. Isolation and characterization of the heavy and the light chains. Eur J Biochem 149:15, 1985
60. Kaplan AP, Joseph K, Silverberg M: Pathways for bradykinin formation and inflammatory disease. J Allergy Clin Immunol 109:195, 2002
61. Silverberg M et al: Autoactivation of human Hageman factor. Demonstration utilizing a synthetic substrate. J Biol Chem 255:7281, 1980
62. Tankersley DL, Finlayson JS: Kinetics of activation and autoactivation of human factor XII. Biochemistry 23:273, 1984
63. Mandle RJ, Kaplan A: Hageman factor substrates. Human plasma prekallikrein: Mechanism of activation by Hageman factor and participation in Hageman factor-dependent fibrinolysis. J Biol Chem 252:6097, 1977
64. Bouma B, Griffin J: Human blood coagulation factor XI. Purification, properties, and mechanism of activation by activated factor XII. J Biol Chem 252:6432, 1977
65. Kurachi K, Davie E: Activation of human factor XI (plasma thromboplastin antecedent) by factor XIIa (activated Hageman factor). Biochemistry 16:5831, 1977
66. Mandle R, Colman R, Kaplan A: Identification of prekallikrein and high-molecular-weight kininogen as a complex in human pl. Proc Natl Acad Sci U S A 73:4179, 1976
67. Thompson R, Mandle RJ, Kaplan A: Association of factor XI and high molecular weight kininogen in human plasma. J Clin Invest 60:1376, 1977
68. Kitamura N et al: Structural organization of the human kininogen gene and a model for its evolution. J Biol Chem 260:8610, 1985
69. Takagaki Y, Kitamura N, Nakanishi S: Cloning and sequence analysis of cDNAs for human high molecular weight and low molecular weight prekininogens. Primary structures of two human prekininog. J Biol Chem 260:8601, 1985
70. Joseph K et al: Identification of the zinc-dependent endothelial cell binding protein for high molecular weight kininogen and factor XII: Identity with the receptor that binds to the globular “heads” of C1q (gC1q-R). Proc Natl Acad Sci U S A 93:8552, 1996
71. Joseph K et al: Interaction of high molecular weight kininogen binding proteins on endothelial cells. Thromb Haemost 91:61, 2004
72. Erdos E, Sloane G: An enzyme in human plasma that inactivates bradykinin and kallidins. Biochem Pharmacol 11:585, 1962
73. Binkley K, Davis AR: Clinical, biochemical, and genetic characterization of a novel estrogen-dependent inherited form of angioedema. J Allergy Clin Immunol 106:546, 2000
74. Bonkowsky H et al: Heme synthetase deficiency in human protoporphyria. Demonstration of the defect in liver and cultured skin fibroblasts. J Clin Invest 56:1139, 1975
75. Sheikh I, Kaplan A: Studies of the digestion of bradykinin, Lys-bradykinin, and des-Arg9-bradykinin by angiotensin converting enzyme. Biochem Pharmacol 35:1951, 1986
76. Yang H, Erdos E: Second kininase in human blood plasma. Nature 215:1402, 1967
77. Sheikh I, Kaplan A: Mechanism of digestion of bradykinin and lysylbradykinin (kallidin) in human serum. Role of carboxypeptidase, angiotensin-converting enzyme and determination of final degradation products. Biochem Pharmacol 38:993, 1989
78. Vavrek R, Stewart J: Competitive antagonists of bradykinin. Peptides 6:161, 1985
79. Regoli D, Barabe J: Pharmacology of bradykinin and related kinins. Pharmacol Rev 32:1, 1980
80. Davis A, Perkins M: The involvement of bradykinin B1 and B2 receptor mechanisms in cytokine-induced mechanical hyperalgesia in the rat. Br J Pharmacol 113:63, 1994
81. Marceau F: Kinin B1 receptors: A review. Immunopharmacology 30:1, 1995
82. Garafalo J, Kaplan A: Histamine release and therapy of severe dermatographism. J Allergy Clin Immunol 68:103, 1981
83. Soter N et al: Delayed cold-induced urticaria: A dominantly inherited disorder. J Allergy Clin Immunol 54:294, 1977
84. Kaplan A: Unusual cold-induced disorders: Cold-dependent dermatographism and systemic cold urticaria. J Allergy Clin Immunol 73:453, 1984
85. Dover J et al: Delayed pressure urticaria. Clinical features, laboratory investigations, and response to therapy of 44 patients. J Am Acad Dermatol 18:1289, 1988
86. Estes S, Yung C: Delayed pressure urticaria: An investigation of some parameters of lesion induction. J Am Acad Dermatol 5:25, 1981
87. Barlow R et al: Adhesion molecule expression and the inflammatory cell infiltrate in delayed pressure urticaria. Br J Dermatol 131:341, 1994
88. Kaplan A, Horakova Z, Katz S: Assessment of tissue fluid histamine levels in patients with urticaria. J Allergy Clin Immunol 61:350, 1978
89. Lawlor F et al: Increased interleukin 6, but reduced interleukin 1, in delayed pressure urticaria. Br J Dermatol 128:500, 1993
90. Weiner M, Metzger W, Simon R: Occupationally acquired vibratory angioedema with secondary carpal tunnel syndrome. Ann Intern Med 98:44, 1983
91. Ting S et al: Nonfamilial, vibration-induced angioedema. J Allergy Clin Immunol 71:546, 1983
92. Siebenhaar F et al: High-dose
desloratadine decreases wheal volume and improves cold provocation thresholds compared with standard-dose treatment in patients with acquired cold urticaria: A randomized, placebo-controlled, crossover study.
J Allergy Clin Immunol 123:672, 2009
93. Costanzi J, Coltman CJ: Kappa chain cold precipitable immunoglobulin G (IgG) associated with cold urticaria. I. Clinical observations. Clin Exp Immunol 2:167, 1967
94. Costanzi J, Coltman CJ, Donaldson V: Activation of complement by a monoclonal cryoglobulin associated with cold urtic. J Lab Clin Med 74:902, 1969
95. Gorevic P: Cryopathies: Cryoblobulins and cryofirinogenemia. In: Samter's Immunologic Diseases, vol. 5, edited by M Frank, K Austen, H Claman. Boston, Little Brown, 1995, p. 951
96. Houser D et al: Cold urticaria. Immunologic studies. Am J Med 49:23, 1970
97. Wanderer A et al: Immunologic characterization of serum factors responsible for cold urticaria. J Allergy Clin Immunol 48:13, 1971
98. Grandel K et al: Association of platelet-activating factor with primary acquired cold urticaria. N Engl J Med 313:405, 1985
99. Kaplan A et al: In vivo studies of mediator release in cold urticaria and cholinergic urticaria. J Allergy Clin Immunol 55:394, 1975
100. Ormerod A et al: Prostaglandin D2 and histamine release in cold urticaria unaccompanied by evidence of platelet activation. J Allergy Clin Immunol 82:586, 1988
101. Soter N, Wasserman S, Austen K: Cold urticaria: Release into the circulation of histamine and eosinophil chemotactic factor of anaphylaxis during cold challenge. N Engl J Med 294:687, 1976
102. Tillie-Leblond I et al: Tumor necrosis factor-alpha release during systemic reaction in cold urticaria. J Allergy Clin Immunol 93:501, 1994
103. Wasserman S, Austen K, Soter N: The functional and physicochemical characterization of three eosinophilotactic activities released into the circulation by cold challenge of patients with cold urticaria. Clin Exp Immunol 47:570, 1982
104. Wasserman S et al: Cold urticaria. Recognition and characterization of a neutrophil chemotactic factor which appears in serum during experimental cold challenge. J Clin Invest 60:189, 1977
105. Kaplan A et al: Idiopathic cold urticaria: In vitro demonstration of histamine release upon challenge of skin biopsies. N Engl J Med 305:1074, 1981
106. Eady R, Greaves M: Induction of cutaneous vasculitis by repeated cold challenge in cold Lancet 1:336, 1978
107. Eady R et al: Cold urticaria with vasculitis: Report of a case with light and electron microscopic, immunofluorescence and pharmacological studies. Clin Exp Dermatol 6:355, 1981
108. Soter N et al: Cutaneous necrotizing venulitis: A sequential analysis of the morphological alterations occurring after mast cell degranulation in a patient with a unique syndrome. Clin Exp Immunol 32:46, 1978
109. Wanderer A et al: Urticarial leukocytoclastic vasculitis with cold urticaria. Report of a case and review of the literature. Arch Dermatol 119:145, 1983
110. Kurtz A, Kaplan A: Regional expression of cold urticaria. J Allergy Clin Immunol 86:272, 1990
111. Czarnetzki B, Frosch P, Sprekeler R: Localized cold reflex urticaria. Br J Dermatol 104:83, 1981
112. Ting S, Mansfield L: Localized cold-reflex urticaria. J Allergy Clin Immunol 75:421, 1985
113. Hoffman H, Wanderer A, Broide D: Familial cold autoinflammatory syndrome: Phenotype and genotype of an autosomal dominant periodic fever. J Allergy Clin Immunol 108:615, 2001
114. Hoffman H et al: Mutation of a new gene encoding a putative pyrin-like protein causes familial cold autoinflammatory syndrome and Muckle-Wells syndrome. Nat Genet 29:301, 2001
115. Gandhi C et al: Familial atypical cold urticaria: Description of a new hereditary disease. J Allergy Clin Immunol 124:1245, 2009
116. Grant R, Pearson R, Comeau W: Observations on urticaria provoked by emotion, by exercise, and by warming the body. Clin Sci 2:266, 1935
117. Commens C, Greaves M: Tests to establish the diagnosis in cholinergic urticaria. Br J Dermatol 98:47, 1978
118. Herxheimer A: The nervous pathway mediating cholinergic urticaria. Clin Sci 15:195, 1956
119. Soter N et al: Release of mast-cell mediators and alterations in lung function in patients with cholinergic urticaria. N Engl J Med 302:604, 1980
120. Fukunaga A et al: Responsiveness to autologous sweat and serum in cholinergic urticaria classifies its clinical subtypes. J Allergy Clin Immunol 116:397, 2005
121. Onn A, Levo Y, Kivity S: Familial cholinergic urticaria. J Allergy Clin Immunol 98:847, 1996
122. Ormerod A et al: Combined cold urticaria and cholinergic urticaria–clinical characterization and laboratory findings. Br J Dermatol 118:621, 1988
123. Sigler R et al: Evaluation of a patient with cold and cholinergic urticaria. J Allergy Clin Immunol 63:35, 1979
124. Kaplan A, Garofalo J: Identification of a new physically induced urticaria: Cold-induced cholinergic urticaria. J Allergy Clin Immunol 68:438, 1981
125. Grant J et al: Local heat urticaria/angioedema: Evidence for histamine release without complement activation. J Allergy Clin Immunol 67:75, 1981
126. Uetsu N et al: The clinical and photobiological characteristics of solar urticaria in 40 patients. Br J Dermatol 142:32, 2000
127. Harber L, Holloway R, Sheatley V: Immunologic and biophysical studies in solar urticaria. J Invest Dermatol 41:439, 1963
128. Sams WJ, Epstein J, Winkelmann R: Solar urticaria. Investigation of pathogenetic mechanisms. Arch Dermatol 99:390, 1969
129. Gigli I et al: Erythropoietic protoporphyria. Photoactivation of the complement system. J Clin Invest 66:517, 1980
130. Lim H et al: Generation of chemotactic activity in serum from patients with erythropoietic protoporphyria and porphyria cutanea tarda. N Engl J Med 304:212, 1981
131. Lim H, Poh-Fitzpatrick M, Gigli I: Activation of the complement system in patients with porphyrias after irradiation in vivo. J Clin Invest 74:1961, 1984
132. Hawk J et al: Elevated blood histamine levels and mast cell degranulation in solar urticaria. Br J Clin Pharmacol 9:183, 1980
133. Soter N, Wasserman S, Pathak M: Solar urticaria: Release of mast cell mediators into the circulation after experimental challenge. J Invest Dermatol 72:283, 1979
134. Casale T, Keahey T, Kaliner M: Exercise-induced anaphylactic syndromes. Insights into diagnostic and pathophysiologic fea. JAMA 255:2049, 1986
135. Lewis J et al: Exercise-induced urticaria, angioedema, and anaphylactoid episodes. J Allergy Clin Immunol 68:432, 1981
136. Sheffer A, Austen K: Exercise-induced anaphylaxis. J Allergy Clin Immunol 66:106, 1980
137. Sheffer A et al: Exercise-induced anaphylaxis: A distinct form of physical allergy. J Allergy Clin Immunol 71:311, 1983
138. Kidd JM 3rd et al: Food-dependent exercise-induced anaphylaxis. J Allergy Clin Immunol 71:407, 1983
139. Kivity S et al: The effect of food and exercise on the skin response to compound 48/80 in patients with food-associated exercise-induced urticaria-angioedema. J Allergy Clin Immunol 81:1155, 1988
140. Maulitz R, Pratt D, Schocket A: Exercise-induced anaphylactic reaction to shellfish. J Allergy Clin Immunol 63:433, 1979
141. Novey H et al: Postprandial exercise-induced anaphylaxis. J Allergy Clin Immunol 71:498, 1983
142. Shadick N et al: The natural history of exercise-induced anaphylaxis: Survey results from a 10-year follow-up study. J Allergy Clin Immunol 104:123, 1999
143. Luong K, Nguyen L: Aquagenic urticaria: Report of a case and review of the literature. Ann Allergy Asthma Immunol 80:483, 1998
144. Poley GJ, Slater J: Latex allergy. J Allergy Clin Immunol 105:1054, 2000
145. Kurup V, Fink J: The spectrum of immunologic sensitization in latex allergy. Allergy 56:2, 2001
146. Millikan L: Papular urticaria. In: Urticaria and Angioedema, edited by M Greaves, A Kaplan. Basel, Marcel Dekker, 2004, p. 251
147. Pixley R, Schapira M, Colman R: The regulation of human factor XIIa by plasma proteinase inhibitors. J Biol Chem 260:1723, 1985
148. Schreiber A, Kaplan A, Austen K: Inhibition by C1INH of Hagemann factor fragment activation of coagulation, fibrinolysis, and kinin generation. J Clin Invest 52:1402, 1973
149. Harpel P, Lewin M, Kaplan A: Distribution of plasma kallikrein between C-1 inactivator and alpha 2-macroglobulin in plasma utilizing a new assay for alpha 2-macroglobulin-kallikrein complexes. J Biol Chem 260:4257, 1985
150. Wuillemin W et al: Inactivation of factor XIa in human plasma assessed by measuring factor XIa-protease inhibitor complexes: Major role for C1-inhibitor. Blood 85:1517, 1995
151. Donaldson V, Evans R: A biochemical abnormality in hereditary angioneurotic edema. Am J Med 35:37, 1963
152. Kramer J et al: Synthesis of C1 inhibitor in fibroblasts from patients with type I and type II hereditary angioneurotic edema. J Clin Invest 87:1614, 1991
153. Caldwell J et al: Acquired C1 inhibitor deficiency in lymphosarcoma. Clin Immunol Immunopathol 1:39, 1972
154. Hauptmann G et al: Acquired C1-inhibitor deficiencies in lymphoproliferative diseases with serum immunoglobulin abnormalities. A study of three cases. Blut 32:195, 1976
155. Schreiber A et al: Acquired angioedema with lymphoproliferative disorder: Association of C1 inhibitor deficiency with cellular abnormality. Blood 48:567, 1976
156. Donaldson V, Hess E, McAdams A: Lupus-erythematosus-like disease in three unrelated women with hereditary angioneurotic edema. Ann Intern Med 86:312, 1977
157. Geha R et al: Acquired C1-inhibitor deficiency associated with antiidiotypic antibody to monoclonal immunoglobulins. N Engl J Med 312:534, 1985
158. Alsenz J, Bork K, Loos M: Autoantibody-mediated acquired deficiency of C1 inhibitor. N Engl J Med 316:1360, 1987
159. Malbran A et al: Acquired angioedema: Observations on the mechanism of action of autoantibodies directed against C1 esterase inhibitor. J Allergy Clin Immunol 81:1199, 1988
160. Zuraw B, Curd J: Demonstration of modified inactive first component of complement (C1) inhibitor in the plasmas of C1 inhibitor-deficient patients. J Clin Invest 78:567, 1986
161. He S, Sim R, Whaley K: Mechanism of action of anti-C1-inhibitor autoantibodies: Prevention of the formation of stable C1s-C1-inh complexes. Mol Med 4:119, 1998
162. Jackson J et al: Autoantibody facilitated cleavage of C1-inhibitor in autoimmune angioedema. J Clin Invest 83:698, 1989
163. Austen KF, Sheffer AL: Detection of hereditory angioneurotic edema by demonstration of a reduction in the second component of human complement. N Engl J Med 272:649, 1965
164. Zuraw B, Sugimoto S, Curd J: The value of rocket immunoelectrophoresis for C4 activation in the evaluation of patients with angioedema or C1-inhibitor deficiency. J Allergy Clin Immunol 78:1115, 1986
165. Curd J, Yelvington M, Burridge N: Generation of bradykinin during incubation of hereditary angioedema plasma. Mol Immunol 19:1365, 1983
166. Fields T, Ghebrehiwet B, Kaplan AP: Kinin formation in hereditary angioedema plasma: Evidence against kinin derivation from C2 and in support of “spontaneous” formation of bradykinin. J Allergy Clin Immunol 72:54, 1983
167. Shoemaker L et al: Hereditary angioneurotic oedema: Characterization of plasma kinin and vascular permeability-enhancing activities. Clin Exp Immunol 95:22, 1994
168. Juhlin L, Michaelsson G: Vascular reactions in hereditary angioneurotic edema. Acta Derm Venereol 40:20, 1969
169. Nussberger J et al: Plasma bradykinin in angioedema. Lancet 351:1693, 1998
170. Schapira M et al: Prekallikrein activation and high-molecular-weight kininogen consumption in hereditary angioedema. N Engl J Med 308:1050, 1983
171. Talamo R, Haber E, Austen K: A radioimmunoassay for bradykinin in plasma and synovial fluid. J Lab Clin Med 74:816, 1969
172. Ghebrehiwet B et al: Mechanisms of activation of the classical pathway of complement by Hageman factor fragment. J Clin Invest 71:1450, 1983
173. Curd J, Prograis LJ, Cochrane C: Detection of active kallikrein in induced blister fluids of hereditary angioedema patients. N Engl J Med 152:742, 1980
174. Cugno M et al: Activation of factor XII and cleavage of high molecular weight kininogen during acute attacks in hereditary and acquired C1-inhibitor deficiencies. Immunopharmacology 33:361, 1996
175. Zahedi R et al: Unique C1 inhibitor dysfunction in a kindred without angioedema. II. Identification of an Ala443–>Val substitution and functional analysis of the recombinant mutant protein. J Clin Invest 95:1299, 1995
176. Zahedi R, Wisnieski J, Davis AE3rd: Role of the P2 residue of complement 1 inhibitor (Ala443) in determination of target protease specificity: Inhibition of complement and contact system proteases. J Immunol 159:983, 1997
177. Nussberger J et al: Local bradykinin generation in hereditary angioedema. J Allergy Clin Immunol 104:1321, 1999
178. Han E et al: Increased vascular permeability in C1 inhibitor-deficient mice mediated by the bradykinin type 2 receptor. J Clin Invest 8:1057, 2002
179. Bork K et al: Hereditary angioedema with normal C1-inhibitor activity in women. Lancet 356:213, 2000
180. Dewald G, Bork K: Missense mutations in the coagulation factor XII (Hageman factor) gene in hereditary angioedema with normal C1 inhibitor. Biochem Biophys Res Commun 343:1286, 2006
181. Bork K, Gul D, Dewald G: Hereditary angio-oedema with normal C1 inhibitor in a family with affected women and men. Br J Dermatol 154:542, 2006
182. Sabroe R, Black A: Angiotensin-converting enzyme (ACE) inhibitors and angio-oedema. Br J Dermatol 136:153, 1997
183. Kaplan A, Greaves M: Angioedema. J Am Acad Dermatol 53:373, 2005
184. Alabaster V, Bakhle Y: Converting enzyme and bradykinin use in the lung. Circ Res 31:72, 1992
185. Joseph K, Tholanikunnel B, Kaplan A: Heat shock protein 90 catalyzes activation of the prekallikrein-kininogen complex in the absence of factor XII. Proc Natl Acad Sci U S A 99:896, 2002
186. Shariat-Madar Z, Mahdi F, Schmaier A: Identification and characterization of prolylcarboxypeptidase as an endothelial cell prekallikrein activator. J Biol Chem 277:17962, 2002
187. Soter N, Austen K, Gigli I: Urticaria and arthralgias as manifestations of necrotizing angiitis (vasculitis). J Invest Dermatol 63:485, 1974
188. Soter N et al: Two distinct cellular patterns in cutaneous necrotizing angiitis. J Invest Dermatol 66:344, 1976
189. Agnello V et al: C1g precipitins in the sera of patients with systemic lupus erythematosus and other hypocomplementemic states: Characterization of high and low molecular weight types. J Exp Med 134:228s, 1971
190. Feig P et al: Vasculitis with urticaria, hypocomplementemia, and multiple system involvement. JAMA 236:2065, 1976
191. Gammon W, Wheeler CJ: Urticarial vasculitis: Report of a case and review of the literature. Arch Dermatol 115:76, 1979
192. Ludivico C, Myers A, Maurer K: Hypocomplementemic urticarial vasculitis with glomerulonephritis and pseudotumor cerebri. Arth Rheum 22:1024, 1979
193. Marder R et al: C1q deficiency associated with urticarial-like lesions and cutaneous vasculitis. Am J Med 61:560, 1976
194. McDuffie F et al: Hypocomplementemia with cutaneous vasculitis and arthritis. Possible immune complex syndrome. Mayo Clin Proc 48:340, 1973
195. Moorthy A, Pringle D: Urticaria, vasculitis, hypocomplementemia, and immune-complex glomerulonephritis. Arch Pathol Lab Med 106:68, 1982
196. Wisnieski J, Naff G: Serum IgG antibodies to C1q in hypocomplementemic urticarial vasculitis syndrome. Arth Rheum 32:1119, 1989
197. Zeiss C et al: A hypocomplementemic vasculitic urticarial syndrome. Report of four new cases and definition of the disease. Am J Med 68:867, 1980
198. Mortureux P et al: Acute urticaria in infancy and early childhood: A prospective study. Arch Dermatol 134:319, 1998
199. Szczeklik A, Gryglewski R, Czerniawska-Mysik G: Relationship of inhibition of prostaglandin biosynthesis by analgesics to asthma attacks in aspirin-sensitive patients. Br Med J 1:67, 1975
200. Mastalerz L et al: Hypersensitivity to
aspirin: Common eicosanoid alterations in urticaria and asthma.
J Allergy Clin Immunol 113:771, 2004
201. Sanchez Borges M et al: Tolerability to new COX-2 inhibitors in NSAID-sensitive patients with cutaneous reactions. Ann Allergy Asthma Immunol 87:201, 2001
202. Israel E et al: The pivotal role of 5-lipoxygenase products in the reaction of aspirin-sensitive asthmatics to
aspirin.
Am Rev Respir Dis 148:1447, 1993
203. Di Campli C et al: Beneficial effects of Helicobacter pylori eradication on idiopathic chronic urticaria. Dig Dis Sci 43:1226, 1998
204. Liutu M et al: Etiologic aspects of chronic urticaria. Int J Dermatol 37:515, 1998
205. Wedi B et al: Prevalence of Helicobacter pylori-associated gastritis in chronic urticaria. Int Arch Allergy Immunol 116:288, 1998
206. Becker H, Meyer M, Paul E: Remission ratio of chronic urticaria – “spontaneous” healing or result of eradication of Helicobacter pylori? Hautarzt 49:907, 1998
207. Hidvegi B et al: The effect of heat-inactivated Helicobacter pylori on the blastogenic response of peripheral blood mononuclear cells of patients with chronic urticaria. Int Arch Allergy Immunol 126:167, 2001
208. Schnyder B, Helbling A, Pichler W: Chronic idiopathic urticaria: Natural course and association with Helicobacter pylori infection. Int Arch Allergy Immunol 119:60, 1999
209. Valsecchi R, Pigatto P: Chronic urticaria and Helicobacter pylori. Acta Derm Venereol 78:440, 1998
210. Greaves M: Chronic idiopathic urticaria and Helicobacter pylori–Not directly causative but could there be a link. Allergy Clin Immunol Int 13:23, 2001
211. Gleich G et al: Episodic angioedema associated with eosinophilia. N Engl J Med 310:1621, 1984
212. Lipsker D et al: The Schnitzler syndrome. Four new cases and review of the literature. Medicine 80:37, 2001
213. Sabroe R et al: The autologous serum skin test: A screening test for autoantibodies in chronic idiopathic urticaria. Br J Dermatol 140:446, 1999
214. Hoskin S et al: Basophil infiltration of weals in chronic idiopathic urticaria J Allergy Clin Immunol 109:S87, 2002
215. Hermes B et al: Upregulation of TNF-α and IL-3 expression in lesional and uninvolved skin in different types of urticaria. J Allergy Clin Immunol 103:307, 1999
216. Toubi E et al: Immune aberrations in B and T lymphocytes derived from chronic urticaria patients. J Clin Immunol 20:371, 2000
217. Kaplan A: What the first 10,000 patients with chronic urticaria have taught me: a personal journey. J Allergy Clin Immunol 123:713, 2009
218. Grob J, Gaudy-Marqueste C: Urticaria and quality of life. Clin Rev Allergy Immunol 30:47, 2006
219. O'Donnell B et al: The impact of chronic urticaria on the quality of life. Br J Dermatol 136:197, 1997
220. Poon E et al: The extent and nature of disability in different urticarial conditions. Br J Dermatol 140:667, 1999
221. Moore-Robinson M, Warin R: Some clinical aspects of cholinergic urticaria. Br J Dermatol 80:794, 1968
222. Zuberbier T et al: Double-blind crossover study of high-dose
cetirizine in cholinergic urticaria.
Dermatology 193:324, 1996
223. Keahey T, Greaves M: Cold urticaria. Dissociation of cold-evoked histamine release and urticara following cold challenge. Arch Dermatol 116:174, 1980
224. Sigler R et al: The role of
cyproheptadine in the treatment of cold urticaria.
J Allergy Clin Immunol 65:309, 1980
225. Wanderer A, Ellis E: Treatment of cold urticaria with
cyproheptadine.
J Allergy Clin Immunol 48:366, 1971
226. Wanderer A, St Pierre J, Ellis E: Primary acquired cold urticaria. Double-blind comparative study of treatment with
cyproheptadine,
chlorpheniramine, and placebo.
Arch Dermatol 131:1375, 1977
227. Kaplan A: Clinical practice. Chronic urticaria and angioedema. N Engl J Med 346:175, 2002
228. Grattan C et al: Randomized double-blind study of cyclosporin in chronic ‘idiopathic’ urticaria. Br J Dermatol 143:365, 2000
229. Toubi E et al: Low-dose cyclosporin A in the treatment of severe chronic idiopathic urticaria. Allergy 52:312, 1997
230. Grattan C et al: Plasmapheresis for severe, unremitting, chronic urticaria. Lancet 339:1078, 1992
231. O'Donnell B et al: Intravenous immunoglobulin in autoimmune chronic urticaria. Br J Dermatol 138:101, 1998
232. Kaplan A et al: Treatment of chronic autoimmune urticaria with
omalizumab.
J Allergy Clin Immunol 122:569, 2008
233. Dreyfus D: Observations on the mechanism of
omalizumab as a steroid-sparing agent in autoimmune or chronic idiopathic urticaria and angioedema.
Ann Allergy Asthma Immunol 100:624, 2008
234. Spector S, Tan R: Effect of
omalizumab on patients with chronic urticaria.
Ann Allergy Asthma Immunol 99:190, 2007
235. Lopez L et al: The hypocomplementemic urticarial-vasculitis syndrome: Therapeutic response to
hydroxychloroquine.
J Allergy Clin Immunol 73:600, 1984
236. Bork K et al: Treatment of acute edema attacks in hereditary angioedema with a bradykinin receptor-2 antagonist (
Icatibant).
J Allergy Clin Immunol 119:1497, 2007
237. Schneider L et al: Critical role of kallikrein in hereditary angioedema pathogenesis: A clinical trial of
ecallantide, a novel kallikrein inhibitor.
J Allergy Clin Immunol 120:416, 2007
238. Sheffer A, Fearon D, Austen K: Hereditary angioedema: A decade of management with stanozolol. J Allergy Clin Immunol 80:855, 1987
239. Sheffer AL, Fearon DT, Austen KF: Clinical and biochemical effects of stanozolol therapy for hereditary angioedema. J Allergy Clin Immunol 68:181, 1981
240. Sheffer A, Austen K, Rosen F: Tranexamic acid therapy in hereditary angioneurotic edema. N Engl J Med 287:452, 1972
241. Frank M et al: Epsilon aminocaproic acid therapy of hereditary angioneurotic edema. A double-blind study. N Engl J Med 286:808, 1972
242. Gelfand JA et al: Treatment of hereditary angioedema with
danazol. Reversal of clinical and biochemical abnormalities.
N Engl J Med 295:1444, 1976